Evidence map›Paper›PMID 32276618›Full record

ArticleBMC infectious diseases2020

Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.

Masanja Robert, Jim Todd, Bernard J Ngowi, Sia E Msuya, Angella Ramadhani, Veryhel Sambu, Isaya Jerry, Martin R Mujuni, Michael J Mahande, James S Ngocho and 1 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masanja RobertDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania. robertmasanja@gmail.com.
Jim ToddDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania.
Bernard J NgowiNational Institute for Medical Research-Muhimbili Medical Research Centre, P.O.Box 3436, Dar es Salaam, Tanzania.
Sia E MsuyaDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania.
Angella RamadhaniMinistry of Health, Community Development, Gender, Elderly and Children (NACP), Dodoma, Tanzania.
Veryhel SambuMinistry of Health, Community Development, Gender, Elderly and Children (NACP), Dodoma, Tanzania.
Isaya JerryMinistry of Health, Community Development, Gender, Elderly and Children (NACP), Dodoma, Tanzania.
Martin R MujuniDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania.
Michael J MahandeDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania.
James S NgochoDepartment of Epidemiology and Biostatistics, Institute of Public Health Kilimanjaro Christian Medical University College (KCMUCo), P.O.Box 2240, Kilimanjaro, Tanzania.
Werner MaokolaMwenge Catholic University (MWECAU), P.O.Box 1226, Moshi, Tanzania.

Funding

This work was supported through the DELTAS Africa Initiative Grant No. 107754/Z/15/Z-DELTAS Africa SSACAB. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Scie 107754/Z/15/Z
6 · The paper itself

Abstract

backgroundTuberculosis (TB) disease is a common opportunistic infection among people living with HIV (PLHIV). WHO recommends at least 6 months of isoniazid Preventive Therapy (IPT) to reduce the risk of active TB. It is important to monitor the six-month IPT completion since a suboptimal dose may not protect PLHIV from TB infection. This study determined the six-month IPT completion and factors associated with six-month IPT completion among PLHIV aged 15 years or more in Dar es Salaam region, Tanzania.

methodsSecondary analysis of routine data from PLHIV attending 58 care and treatment clinics in Dar es Salaam region was used. PLHIV, aged 15 years and above, who screened negative for TB symptoms and initiated IPT from January, 2013 to June, 2017 were recruited. Modified Poisson regression with robust standard errors was used to estimate prevalence ratios (PR) and 95% confidence interval (CI) for factors associated with IPT completion. Multilevel analysis was used to account for health facility random effects in order to estimate adjusted PR (APR) for factors associated with IPT six-month completion.

resultsA total of 29,382 PLHIV were initiated IPT, with 21,808 (74%) female. Overall 17,092 (58%) six-month IPT completion, increasing from 42% (773/1857) in year 2013 to 76% (2929/3856) in 2017. Multilevel multivariable model accounting for health facilities as clusters, showed PLHIV who were not on ART had 46% lower IPT completion compared to those were on ART (APR: 0.54: 95%CI: 0.45-0.64). There was 37% lower IPT completion among PLHIV who transferred from another clinic (APR: 0.63: 95% CI (0.54-0.74) compared to those who did not transfer. PLHIV aged 25-34 years had a 6% lower prevalence of IPT completion as compared to those aged 15 to 24 years (APR:0.94 95%CI:0.89-0.98).

conclusionThe IPT completion rate in PLHIV increased over time, but there was lower IPT completion in PLHIV who transferred from other clinics, who were aged 25 to 34 years and those not on ART. Interventions to support IPT in these groups are urgently needed.

Indexed as

AdolescentAdultAIDS-Related Opportunistic InfectionsAntibiotic ProphylaxisAntitubercular AgentsCross-Sectional StudiesFemaleHIV InfectionsHumansIsoniazidLatent TuberculosisMaleMiddle AgedMultilevel AnalysisTanzaniaTuberculosisAntitubercular AgentsIsoniazidHIVIPT completionPredictorsTanzaniaTuberculosis

Identifiers

PMID32276618
PMCPMC7147031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.